Cited by 474Pharmaceutical Economics and PolicyPharmaceutical industry and healthcareHistorical Medical Research and Treatments

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).

Open access

Prentis, RA, Lis, Y, Walker, SR·1988·British Journal of Clinical Pharmacology

DOI 10.1111/j.1365-2125.1988.tb03318.xPMC PMC1386364

Open this paper in CoChat — free account Open PDF

Abstract

1 A total of three hundred and nineteen new chemical entities (NCEs) were investigated in man for the first time between 1964 and 1985 by seven UK‐owned pharmaceutical companies. The majority (96.2%), were self‐originated by the UK company or one of its overseas subsidiaries. 2 There was an increase in the number of NCEs investigated each year in man, doubling from an average of 12 per year up to 1980, to over 20 per year between 1981 and 1985. The majority of first drug evaluations in human volunteers were carried out in the UK (92.2%), in contrast to evaluation of new medicines in patients, where 42.9% were first tested outside the UK. 3 The majority of NCEs evaluated in man (78%), were in four therapeutic classes: anti‐infectives (32%), anti‐allergics (22%), drugs acting on the central nervous system (13%) and cardiovascular system agents (11%). 4 By the end of 1985, 49 (15.4%) of these NCEs had been marketed in the UK and 198 (62.0%) discontinued from further development. The main reasons for termination were inappropriate pharmacokinetics in man (39.4%), and lack of clinical efficacy (29.3%). 5 Average development times increased from less than 2 years between 1964 and 1965, to around 8 years in the 1980s with a consequent reduction in the effective patent life.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.1988.tb03318.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New drug development in the United States, 1963 through 1984
Mattison, N., Trimble, A. G., & Lasagna, L. C. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.35 · Cited by 53
Drug innovation—what's slowing it down?
Steward, F., & Wibberley, G. (1980) · Nature · doi:10.1038/284118a0 · Cited by 44
The rate of development of new drugs in the United States, 1963 through 1975
Wardell, W. M., Hassar, M., & Anavekar, S. N. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978242133 · Cited by 32
A survey of products licensed in the United Kingdom from 1971‐1981.
Griffin, J. L., & Diggle, G. E. (1981) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1981.tb01251.x · Cited by 27
The Measurement of Pharmaceutical Innovation
Wardell, W. M., & DiRaddo, J. (1980) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1980.tb01660.x · Cited by 21
Pharmaceuticals in seven nations
Chew, R., Smith, G. T., & Wells, N. E. J. (1985) · Monographs · Cited by 18
Trends in the development of new medicines by UK‐owned pharmaceutical companies (1964‐1980).
Prentis, R., & Walker, S. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb05219.x · Cited by 16
Self-citation
A survey of the first year of operation of the new procedure affecting the conduct of clinical trials in the United Kingdom.
Speirs, C., & Griffin, J. P. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb01545.x · Cited by 15
Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980.
Wardell, W. M., & Le, S. (1983) · PubMed · Cited by 10
The development of self-originated new drugs by Swiss pharmaceutical firms, 1960–1980
Mattison, N., Thomas, E., Trimble, A. G., & Wardell, W. M. (1984) · Regulatory Toxicology and Pharmacology · doi:10.1016/0273-2300(84)90038-2 · Cited by 10

Show all 12 references

Research works printed but not linked: 7

Hass A. E., 1985, New drugs: Their market life and safety, Pharm. J., 234, 235
Lumley C. E., 1987, Trends in research and development expenditure by the UK pharmaceutical industry (1982–84), Pharm. Med.
Reis‐Arndt E., 1975, New pharmaceutical agents 1961–1973, Drugs made in Germany, 18, 123
Reis‐Arndt E., 1982, 20 Jahre Arzneimittelentwick — lung — Neue pharmazeutische Wirkstoffe 1961–1980, Pharmac. Ind., 44, 1115
Speirs C. J. Saunders R. M.&Griffin J. P.(1984).The UK Clinical Trial Exemption scheme — its effects on investment in researchPharm. Int. Oct. 254–256.
Walker S. R., 1982, Innovation and drug development — Can the process be expedited, BIRA Journal, 1, 34
Walker S. R., 1985, Drug Research & Pharmaceutical Patents, Pharm. J., 234, 11

Sorted by citations

Fluorine in medicinal chemistry
Purser, S., Moore, P. R., Swallow, S., & Gouverneur, V. (2007) · Chemical Society Reviews · doi:10.1039/b610213c · Cited by 7,678
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Cyclodextrin-based pharmaceutics: past, present and future
Davis, M. E., & Brewster, M. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1576 · Cited by 2,057
Prediction of Drug Absorption Using Multivariate Statistics
Egan, W. J., Merz, K. M., & Baldwin, J. J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000292e · Cited by 2,051
Cyclodextrins as pharmaceutical solubilizers
Brewster, M. E., & Loftsson, Þ. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.012 · Cited by 1,942
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Role of Pharmacokinetics and Metabolism in Drug Discovery and Development
Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 713
Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics
Waterbeemd, H. V. D., Smith, D. A., Beaumont, K. C., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 606
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 550
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
Ingelman‐Sundberg, M., Oscarson, M., & McLellan, R. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01363-2 · Cited by 539
The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs
Kipp, J. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.07.019 · Cited by 530
Bottom-up approaches for preparing drug nanocrystals: Formulations and factors affecting particle size
Sinha, B., Müller, R. H., & Möschwitzer, J. P. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.019 · Cited by 527
Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery
Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.554 · Cited by 500
High-Throughput Permeability pH Profile and High-Throughput Alkane/Water logPwith Artificial Membranes
Wohnsland, F., & Faller, B. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001020e · Cited by 495
Delivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations
Thorne, R. G., & Frey, W. H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140120-00003 · Cited by 487
A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity
Astashkina, A. I., Mann, B. K., & Grainger, D. W. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.001 · Cited by 455
The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 377
Drug research: myths, hype and reality
Kubinyi, H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1156 · Cited by 348
High throughput physicochemical profiling for drug discovery
Kerns, E. H. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1134 · Cited by 340
The importance of the domain of applicability in QSAR modeling
Weaver, S., & Gleeson, M. P. (2008) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2008.01.002 · Cited by 339
Amorphous Drug Delivery Systems: Molecular Aspects, Design, and Performance
Kaushal, A. M., Gupta, P., & Bansal, A. K. (2004) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v21.i3.10 · Cited by 314
Preparation and Characterization of Nanofibers Containing Amorphous Drug Dispersions Generated by Electrostatic Spinning
Verreck, G., Chun, I., Peeters, J., Rosenblatt, J., & Brewster, M. E. (2003) · Pharmaceutical Research · doi:10.1023/a:1023450006281 · Cited by 312
Pharmacokinetics
Fan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309
In silico prediction of drug‐binding strengths to human serum albumin
Colmenarejo, G. (2003) · Medicinal Research Reviews · doi:10.1002/med.10039 · Cited by 292
Pharmaceutical profiling in drug discovery
Kerns, E. H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02649-7 · Cited by 292
Cytochromes P450 as useful biocatalysts: addressing the limitations
O’Reilly, E., Köhler, V., Flitsch, S. L., & Turner, N. J. (2011) · Chemical Communications · doi:10.1039/c0cc03165h · Cited by 283
Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
Lappin, G., & Garner, R. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1037 · Cited by 260
Dissolution of Ionizable Water‐Insoluble Drugs: The Combined Effect of pH and Surfactant
Jinno, J., Oh, D.-M., Crison, J. R., & Amidon, G. L. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/(sici)1520-6017(200002)89:2 · Cited by 164
Experimental and Computational Screening Models for the Prediction of Intestinal Drug Absorption
Stenberg, P., Norinder, U., Luthman, K., & Artursson, P. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001101a · Cited by 253
ADME/PK as part of a rational approach to drug discovery
Eddershaw, P. J., Beresford, A. P., & Bayliss, M. K. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01540-3 · Cited by 238
Current developments and applications of microfluidic technology toward clinical translation of nanomedicines
Liu, D., Zhang, H., Fontana, F., Hirvonen, J. J., & Santos, H. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.003 · Cited by 241
Prediction of Aqueous Solubility of a Diverse Set of Compounds Using Quantitative Structure−Property Relationships
Cheng, A., & Merz, K. M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020266b · Cited by 237
Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals
Stanton, M. K., & Bak, A. (2008) · Crystal Growth & Design · doi:10.1021/cg800173d · Cited by 240
Applying Mechanisms of Chemical Toxicity to Predict Drug Safety
Guengerich, F. P., & MacDonald, J. S. (2007) · Chemical Research in Toxicology · doi:10.1021/tx600260a · Cited by 234
Comparison of Electrospun and Extruded Soluplus®-Based Solid Dosage Forms of Improved Dissolution
Nagy, Z. K., Balogh, A., Vajna, B., Farkas, A., Patyi, G., Kramarics, Á., & Marosi, G. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22731 · Cited by 226
Metabolism and Toxicity of Drugs. Two Decades of Progress in Industrial Drug Metabolism
Baillie, T. A. (2007) · Chemical Research in Toxicology · doi:10.1021/tx7002273 · Cited by 221
Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes
Perrut, M., Jung, J., & Leboeuf, F. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.09.007 · Cited by 215
High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole
Nagy, Z. K., Balogh, A., Démuth, B., Pataki, H., Vígh, T., Szabó, B., Molnár, K., Schmidt, B. T., Horák, P., Marosi, G., et al. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.025 · Cited by 214
Predicting Human Drug Glucuronidation Parameters: Application of In Vitro and In Silico Modeling Approaches
Miners, J. O., Smith, P. A., Sorich, M. J., McKinnon, R. A., & Mackenzie, P. I. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121546 · Cited by 210
Drug permeation in biomembranes
Mälkiä, A., Murtomäki, L. S., Urtti, A. O., & Kontturi, K. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.05.009 · Cited by 189
Pharmaceutical Amorphous Nanoparticles
Jog, R., & Burgess, D. J. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.09.014 · Cited by 186
Toxicogenomics and drug discovery: will new technologies help us produce better drugs?
Ulrich, R. G., & Friend, S. H. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd710 · Cited by 182
The pivotal role of hepatocytes in drug discovery
Soars, M. G., McGinnity, D. F., Grime, K., & Riley, R. J. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.11.002 · Cited by 172
Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes
McGuckin, M. B., Wang, J., Ghanma, R., Qin, N., Palma, S. D., Donnelly, R. F., & Paredes, A. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.012 · Cited by 182
Prediction of intestinal absorption: comparative assessment of gastroplus™ and idea™
Parrott, N., & Lavé, T. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00132-x · Cited by 170
Biopharmaceutics and pharmacokinetics in drug research
Panchagnula, R. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00344-6 · Cited by 173
Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles
Wais, U., Jackson, A. W., He, T., & Zhang, H. (2015) · Nanoscale · doi:10.1039/c5nr07161e · Cited by 168
Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design
Vandecruys, R., Peeters, J., Verreck, G., & Brewster, M. E. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.05.006 · Cited by 164
Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations
Lav??, T., Coassolo, P., & Reigner, B. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00003 · Cited by 162
Physiologically-based pharmacokinetic simulation modelling
Grass, G. M., & Sinko, P. J. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00013-3 · Cited by 160
In silico prediction of ADME and pharmacokinetics
Boobis, A. R., Gundert‐Remy, U., Kremers, P. G., Macheras, P. E., & Pelkonen, O. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00185-9 · Cited by 154
Interspecies scaling and comparisons in drug development and toxicokinetics
Ings, R. M. J. (1990) · Xenobiotica · doi:10.3109/00498259009046839 · Cited by 152
Optimization of metabolic stability as a goal of modern drug design
Thompson, T. N. (2001) · Medicinal Research Reviews · doi:10.1002/med.1017 · Cited by 151
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Shih, H.-P., Zhang, X., & Aronov, A. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.194 · Cited by 149
The importance of microfluidics for the preparation of nanoparticles as advanced drug delivery systems
Martins, J. P., Torrieri, G., & Santos, H. A. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1446936 · Cited by 152
African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development
Rajman, I., Knapp, L., Morgan, T. M., & Masimirembwa, C. M. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.017 · Cited by 145
Formulation optimization and in situ absorption in rat intestinal tract of quercetin-loaded microemulsion
Gao, Y., Wang, Y., Ma, Y., Yu, A., Cai, F.-H., Shao, W., & Zhai, G. (2009) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.03.005 · Cited by 145
Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo
Soars, M. G., Grime, K., Sproston, J. L., Webborn, P. J. H., & Riley, R. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014464 · Cited by 144
Graphical Model for Estimating Oral Bioavailability of Drugs in Humans and Other Species from Their Caco-2 Permeability and in Vitro Liver Enzyme Metabolic Stability Rates
Mandagere, A. K., Thompson, T. N., & Hwang, K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010152k · Cited by 140
Beyond Size, Ionization State, and Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, Excretion, and Toxicity for Druglike Compounds
Yang, Y., Engkvist, O., Llinàs, A., & Chen, H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201548z · Cited by 139
Applications of Epithelial Cell Culture in Studies of Drug Transport
Tavelin, S., Gråsjö, J., Taipalensuu, J., Ocklind, G., & Artursson, P. (2003) · Humana Press eBooks · doi:10.1385/1-59259-185-x:233 · Cited by 139
Chemoinformatics – predicting the physicochemical properties of 'drug-like' molecules
Blake, J. F. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00062-2 · Cited by 137
Development of a Novel in Vitro Model to Predict Hepatic Clearance Using Fresh, Cryopreserved, and Sandwich-Cultured Hepatocytes
Lau, Y. Y., Sapidou, E., Cui, X., White, R. E., & Cheng, K.-C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1446 · Cited by 132
Transport Characteristics of Fexofenadine in the Caco-2 Cell Model
Petri, N., Tannergren, C., Rungstad, D., & Lennernäs, H. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036913.90332.b1 · Cited by 130
The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development
Walker, D. K. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02194.x · Cited by 130
Drug Design—Past, Present, Future
Doytchinova, I. A. (2022) · Molecules · doi:10.3390/molecules27051496 · Cited by 141
REDUCTION OFN-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES
Clement, B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120005643 · Cited by 119
In Silico Prediction of Caco‐2 Cell Permeability by a Classification QSAR Approach
Pham‐The, H., González‐Álvarez, I., Bermejo, M., Sanjuan, V. M., Centelles, I., Garrigues, T., & Cabrera‐Pérez, M. Á. (2011) · Molecular Informatics · doi:10.1002/minf.201000118 · Cited by 121
Development of predictive pharmacokinetic simulation models for drug discovery
Norris, D. A., Leesman, G. D., Sinko, P. J., & Grass, G. M. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00232-1 · Cited by 108
High‐throughput screening for stability and inhibitory activity of compounds toward cytochrome P450‐mediated metabolism
Ansede, J. H., & Thakker, D. R. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10545 · Cited by 109
Heterologous Expression and Kinetic Characterization of Human Cytochromes P-450: Validation of a Pharmaceutical Tool for Drug Metabolism Research
Masimirembwa, C. M., Otter, C. A., Berg, M., Jönsson, M., Leidvik, B., Jonsson, E., Johansson, T., Bäckman, A., Edlund, A., & Andersson, T. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15034-9 · Cited by 106
Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding
Wu, J., & Ho, P. C. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.05.002 · Cited by 106
Can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges
Basavaraj, S., & Betageri, G. V. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.12.003 · Cited by 110
Development of Quantitative Structure−Property Relationship Models for Early ADME Evaluation in Drug Discovery. 2. Blood-Brain Barrier Penetration
Liu, R., Sun, H., & So, S. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010290i · Cited by 104
Enantiomeric separation and determination of absolute stereochemistry of asymmetric molecules in drug discovery—Building chiral technology toolboxes
McConnell, O. J., Bach, A., Balibar, C. J., Byrne, N., Cai, Y., Carter, G., Chlenov, M. A., Di, L., Fan, K. Y., Goljer, I., et al. (2007) · Chirality · doi:10.1002/chir.20399 · Cited by 106
Investigating the human metabolism of acetaminophen using UPLC and exact mass oa-TOF MS
Johnson, K. A., & Plumb, R. S. (2005) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2005.04.048 · Cited by 104
High-throughput screening approaches for investigating drug metabolism and pharmacokinetics
Roberts, S. (2001) · Xenobiotica · doi:10.1080/00498250110060978 · Cited by 104
A High-Capacity LC/MS System for the Bioanalysis of Samples Generated from Plate-Based Metabolic Screening
Janiszewski, J. S., Rogers, K. J., Whalen, K. M., Cole, M. J., Liston, T. E., Duchoslav, E., & Fouda, H. G. (2001) · Analytical Chemistry · doi:10.1021/ac0013251 · Cited by 103
A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats
Willmann, S., Schmitt, W., Keldenich, J., & Dressman, J. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000003373.72652.c0 · Cited by 98
Structure based medicinal chemistry-driven strategy to design substituted dihydropyrimidines as potential antileishmanial agents
Rashid, U., Sultana, R., Shaheen, N., Hassan, S. F., Yaqoob, F., Ahmad, M. J., Iftikhar, F., Sultana, N., Asghar, S., Yasinzai, M., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.022 · Cited by 97
Human embryonic stem cells: Current technologies and emerging industrial applications
Améen, C., Strehl, R., Björquist, P., Lindahl, A. H., Hyllner, J., & Sartipy, P. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.012 · Cited by 94
Pharmaceutical applications of cyclodextrins and their derivatives
Dhiman, P., & Bhatia, M. (2020) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-020-01029-3 · Cited by 98
Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies – Development of particle design method
Niwa, T., Miura, S., & Danjo, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.013 · Cited by 90
ADME-Space: a new tool for medicinal chemists to explore ADME properties
Bocci, G., Carosati, E., Vayer, P., Arrault, A., Lozano, S., & Cruciani, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-06692-0 · Cited by 91
QSAR Models for the Prediction of Binding Affinities to Human Serum Albumin Using the Heuristic Method and a Support Vector Machine
Xue, C., Zhang, R., Liu, H., Yao, X., Liu, M., Hu, Z., & Fan, B. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci049820b · Cited by 89
The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery
Smith, N. F., Raynaud, F. I., & Workman, P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0324 · Cited by 78
Application of In Silico, In Vitro and Preclinical Pharmacokinetic Data for the Effective and Efficient Prediction of Human Pharmacokinetics
Grime, K., Barton, P., & McGinnity, D. F. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300476z · Cited by 78
Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling
Choi, G.-W., Lee, Y.-B., & Cho, H.-Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040168 · Cited by 79
“One of the main reasons associated with the termination of drug development is inappropriate pharmacokinetic (PK) properties in humans [1].”
Background
Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone
Khan, T., Ahmad, R., Azad, I., Raza, S., Joshi, S., & Khan, A. R. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.05.008 · Cited by 77
Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing
Combes, R. D., Berridge, T., Connelly, J. C., Eve, M. D., Garner, R. C., Toon, S., & Wilcox, P. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(03)00040-x · Cited by 76
Effect of liquid crystals with cyclodextrin on the bioavailability of a poorly water-soluble compound, diosgenin, after its oral administration to rats
Okawara, M., Hashimoto, F., Todo, H., Sugibayashi, K., & Tokudome, Y. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.06.032 · Cited by 75
Theoretical Predictions of Drug Absorption in Drug Discovery and Development
Stenberg, P., m, C. A. S. B., Luthman, K., & Artursson, P. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00005 · Cited by 75
Physiologically Based Pharmacokinetic (PBPK) Modeling of Disposition of Epiroprim in Humans
Luttringer, O., Theil, F., Poulin, P., Schmitt‐Hoffmann, A. H., Guentert, T. W., & Lavé, T. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10461 · Cited by 74
The predictivity of the toxicity of pharmaceuticals in humans from animal data — an interim assessment
Olson, H. M., Betton, G. R., Stritar, J. A., & Robinson, D. E. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00261-6 · Cited by 73
Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole
Kumar, S., Shen, J., & Burgess, D. J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.059 · Cited by 71
EVALUATION OF A NOVEL IN VITRO CACO-2 HEPATOCYTE HYBRID SYSTEM FOR PREDICTING IN VIVO ORAL BIOAVAILABILITY
Lau, Y. Y., Chen, Y., Liu, T., Li, C., Cui, X., White, R. E., & Cheng, K. (2004) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)02976-3 · Cited by 71
Bioanalysis in drug discovery and development
Pandey, S., Pandey, P. M., Tiwari, G., & Tıwarı, R. (2010) · Pharmaceutical Methods · doi:10.4103/2229-4708.72223 · Cited by 74
Advanced screening assays to rapidly identify solubility-enhancing formulations: High-throughput, miniaturization and automation
Dai, W., Pollock‐Dove, C., Dong, L. C., & Li, S. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.017 · Cited by 70
Exploring the novel heterocyclic derivatives as lead molecules for design and development of potent anticancer agents
Azad, I., Nasibullah, M., Khan, T., Hassan, F., & Akhter, Y. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.02.013 · Cited by 70
Untitled work
(2004) · PubMed · Cited by 66

Authors: Prentis, R., Lis, Y., & Walker, Sr.
Venue: British Journal of Clinical Pharmacology
Publisher: Wiley
Published: 1988-03
Volume: 25
Issue: 3
Pages: 387-396
ISSN: 0306-5251 (ISSN-L)
1365-2125
DOI: 10.1111/j.1365-2125.1988.tb03318.x
PMC: PMC1386364
OpenAlex: W2117753715
Cited by: 471
References: 12
Citations by year: 2025: 8 · 2024: 7 · 2023: 11 · 2022: 16 · 2021: 12 · 2020: 10 · 2019: 14 · 2018: 13 · 2017: 17 · 2016: 16 · 2015: 23 · 2014: 22 · 2013: 21 · 2012: 24
FWCI: 8.40
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 8913 d)
Locations: British Journal of Clinical Pharmacology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
Keywords: pharmaceutical innovation, new chemical entities, drug development, drug development time, patent life, drug discontinuation, anti-infective agents, antiallergic drugs, central nervous system drugs, cardiovascular drugs
MeSH terms: Chemistry, Pharmaceutical, Drug Industry, United Kingdom, Humans, Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks